knowledge -WSS

knowledge

author：hotspot 2025-09-10 16:45:46 - browse：722

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Clinical trials giant ICON acquires HumanFirst

knowledge

explore

WSS

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Medical device lobby: We're tired of waiting on Medicare coverage

Plastic surgeons increase patient psychiatric screenings

How to fix the rural physician shortage in the U.S.

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Health AI adoption puts security, privacy startups on investors' radar

Affirmative action in medical school literally saved lives

Leading voice in opioid treatment defends methadone clinic system

Affirmative action in medical school literally saved lives

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Psychedelics group wrestles with new pharma identity

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How to fix the rural physician shortage in the U.S.

hotspot

An inside look at PIPEs, biotech's buzzy new financing tool

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Intermittent fasting comes with a heart risk? Not so fast

In search for therapies for solid tumors, companies turn to claudin

FDA does about

How to fix the rural physician shortage in the U.S.

knowledge

knowledge

explore

knowledge